Table 1.
SARS infection and maternal–fetal outcome.
| Country | Case | Maternal |
Newborn |
|||
|---|---|---|---|---|---|---|
| Complication | SARS-CoV Antibody | Delivery | Complication | SARS-CoV antibody | ||
| United States | 1 | Progressive Lung Infiltration s/p Mechanical Ventilation | Serum (+) | 38 weeks Cesarean Placenta previa |
No adverse effect | Cord blood (+) Placenta (−) Breast milk (+) Stool (−) |
| 2 | Lung infiltration s/p antibiotics | Serum (+) | 36 weeks Cesarean Fetal Distress |
No adverse effect | Cord blood (−) Placenta (−) Breast milk (−) Stool (−) |
|
| Hong Kong | 1 | SARS fatality with MRSA pneumonia | Nasopharyngeal (+) | 28 weeks Cesarean Fetal Distress |
Necrotizing Enterocolitis with ileal perforation s/p laparotomy | Cord blood (−) Placenta (−) Stool (−) Peritoneal fluid (−) |
| 2 | Lung infiltration s/p antibiotics | Stool (+) CSF (+) Peritoneal fluid (+) |
26 weeks Cesarean Fetal Distress |
Jejunal perforation s/p laparotomy | Cord blood (−) Placenta (−) Stool (−) Peritoneal fluid (−) |
|
| 3 | SARS fatality | Stool (+) | 32 weeks Cesarean Maternal Hypoxia |
No adverse effect | Cord blood (−) Placenta (−) Stool (−) |
|
| 4 | Lung infiltration s/p antibiotics | Nasopharyngeal (+) | 33 weeks X Preterm labor |
No adverse effect | Cord blood (−) Placenta (−) Stool (−) |
|
| 5 | Progressive Lung Infiltration s/p Mechanical Ventilation | Stool (+) | 37 weeks NSD |
No adverse effect | Cord blood (−) Placenta (−) Stool (−) |
|
| Others | 4 miscarriage 2 termination |
|||||